The impact of circulating tumor cells (CTCs) detection in metastatic breast cancer (MBC): Implications of “<i>indolent</i>” stage IV disease (Stage IV<sub>indolent</sub>).
Andrew A. Davis(Washington University in St. Louis), Massimo Cristofanilli(Cornell University), Daniele Generali(University of Trieste), Salvatore Grisanti(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Luc Dirix(GZA Ziekenhuizen Campus Sint-Augustinus), Paola Gazzaniga(Sapienza University of Rome), José Á. García-Sáenz(Hospital Clínico San Carlos), José Vidal-Martínez(Hospital Arnau de Vilanova), Elisabetta Munzone(Istituti di Ricovero e Cura a Carattere Scientifico), James M. Reuben(The University of Texas MD Anderson Cancer Center), Alfred Rademaker(Northwestern University), Mario Giuliano(Regione Campania), Stefan Michiels(Institut Gustave Roussy), Justin Stebbing(Anglia Ruskin University), Tanja Fehm(Düsseldorf University Hospital), Sarah‐Jane Dawson(The University of Melbourne), François‐Clément Bidard(Inserm), Dimitriοs Mavroudis(University of Crete), Jean‐Yves Pierga(Université Paris Cité)
Cited by 5
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k